MCID: TRN034
MIFTS: 54

Transverse Myelitis

Categories: Immune diseases, Infectious diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Transverse Myelitis

MalaCards integrated aliases for Transverse Myelitis:

Name: Transverse Myelitis 54 55
Myelitis, Transverse 74
Myelitis Transverse 56

Classifications:



External Ids:

UMLS 74 C0026976

Summaries for Transverse Myelitis

NIH Rare Diseases : 54 Transverse myelitis is a neurological disorder caused by inflammation of the spinal cord, which carries nerve signals from the brain to the rest of the body. The segment of the spinal cord that has inflammation or damage determines the symptoms a person has. Generally, inflammation at one segment causes symptoms at that level and below that level. Most commonly, the upper spinal cord is affected, causing impaired leg movement, and problems controlling the bowel and bladder. The onset of symptoms may be acute (sudden, developing over hours or days) or subacute (developing over weeks). The cause of transverse myelitis may be unknown (idiopathic) or it may be associated with a wide variety of underlying health problems, including infections, immune system disorders, and other inflammatory disorders. Tests that may be used to diagnose transverse myelitis include MRI to look for compression or inflammation of the spinal cord, and a lumbar puncture (spinal tap) to look for evidence of inflammation in the fluid surrounding the spinal cord (cerebrospinal fluid). Treatment options may include intravenous steroids, pain medicines, plasmapheresis (also called plasma exchange), intravenous immunoglobulin (IVIG), and cyclophosphamide. Some people have full or partial recovery from symptoms, while others do not recover any lost function in the affected parts of the body. Most people recover at least partially, although recovery can take up to 2 or 3 years. In general however, if there is no improvement within the first 6 months, a significant recovery is not likely.

MalaCards based summary : Transverse Myelitis, also known as myelitis, transverse, is related to acute transverse myelitis and neuromyelitis optica. An important gene associated with Transverse Myelitis is AQP4 (Aquaporin 4), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Mycophenolic acid and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and testes, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

NINDS : 55 Transverse myelitis is an inflammation of the spinal cord. The inflammation interrupts communications between nerve fibers in the spinal cord and the rest of the body, affectng sensation and nerve signaling below the damage to the protective nerve coating called myelin. The segment of the spinal cord at which the damage occurs determines which parts of the body are affected. Damage at one segment will affect function at that level and below. In people with transverse myelitis, the myelin damage most often occurs in nerves in the upper back, causing problems with leg movement and bowel and bladder control, which require signals from the lower segments of the spinal cord.  Symptoms may develop suddenly or over days or weeks. Classic symptoms include: weakness of the arms and legs, sensory alterations such as burning, pricking, numbness, or sensory loss, pain (usually in the lower back or down the legs and arms or around the torso),  and bowel and bladder dysfunction. Some cases of transverse myelitis occur on their own, but a number of conditions appear to cause the disorder, including immune system disorders, bacteial and viral infections, fungal infections, and various parasites.  Transverse myelitis can affect people of any age, but a peak in incidence rates appears to occur between 10 and 19 years of age and 30 to 39 years of age.

Wikipedia : 77 Transverse myelitis (TM) is a rare neurological condition in which the spinal cord is inflamed.... more...

Related Diseases for Transverse Myelitis

Diseases in the Transverse Myelitis family:

Acute Transverse Myelitis Secondary Acute Transverse Myelitis

Diseases related to Transverse Myelitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 402)
# Related Disease Score Top Affiliating Genes
1 acute transverse myelitis 32.8 APOA1 AQP4 CXCL8 IL10 IL6 MMP2
2 neuromyelitis optica 32.7 AQP4 IL17A IL6 MBP
3 systemic lupus erythematosus 32.1 APOH IL10 IL17A IL6 TNF
4 myelitis 31.9 APOH AQP4 IL17A IL6 MBP TNF
5 neuritis 30.6 AQP4 MBP TNF
6 optic neuritis 30.5 AQP4 MBP TNF
7 acute disseminated encephalomyelitis 30.5 AQP4 IL10 MBP
8 arteriovenous fistula 30.4 APOH IL6 MMP2
9 spondylitis 30.3 IL17A IL6 TNF
10 neurosyphilis 30.2 CXCL8 IL10 IL17A
11 myasthenia gravis 30.1 IL10 MBP TNF
12 lyme disease 30.0 IL17A IL6 MMP9 TNF
13 psoriatic arthritis 30.0 IL17A IL6 TNF
14 pneumonia 30.0 CXCL8 IL10 IL6 TNF
15 mixed connective tissue disease 29.9 APOH IL10 IL6 TNF
16 connective tissue disease 29.9 APOH IL10 IL6 TNF
17 tuberculous meningitis 29.9 CXCL8 MMP9 TNF
18 human immunodeficiency virus infectious disease 29.9 IL10 IL6 TNF
19 cytomegalovirus infection 29.9 CXCL8 IL6 TNF
20 meningitis 29.9 CXCL8 IL10 IL6 MMP9 TNF
21 pertussis 29.9 IL10 IL6 TNF
22 ischemic colitis 29.8 APOH MMP2 MMP9
23 intracranial hypertension 29.8 APOH AQP4 TNF
24 aseptic meningitis 29.7 CXCL8 IL10 TNF
25 melioidosis 29.7 IL10 IL6 TNF
26 colitis 29.6 CXCL8 IL10 IL17A IL6 TNF
27 leptospirosis 29.5 CXCL8 IL10 IL6 TNF
28 brucellosis 29.5 CXCL8 IL10 IL6 TNF
29 osteomyelitis 29.5 CXCL8 IL10 IL6 TNF
30 chlamydia 29.5 CXCL8 IL10 IL6 TNF
31 trypanosomiasis 29.5 CXCL8 IL10 IL6 TNF
32 multiple sclerosis 29.4 AQP4 IL10 IL17A IL6 MBP MMP9
33 common variable immunodeficiency 29.4 CD27 IL10 IL6 TNF
34 arthritis 29.2 CXCL8 IL10 IL17A IL6 MMP9 TNF
35 ulcerative colitis 29.2 CXCL8 IL10 IL17A IL6 TNF
36 spinal cord injury 29.2 AQP4 CXCL8 IL6 MMP9 TNF
37 demyelinating disease 29.2 AQP4 IL10 IL17A MBP MMP9 TNF
38 rheumatoid arthritis 29.1 CXCL8 IL10 IL17A IL6 MMP9 TNF
39 idiopathic acute transverse myelitis 12.6
40 secondary acute transverse myelitis 12.5
41 acute flaccid myelitis 11.8
42 antiphospholipid syndrome 11.6
43 thyrotoxic periodic paralysis 11.3
44 lupus - neurological sequelae 11.3
45 paresthesia 11.3
46 lupus erythematosus 10.7
47 hepatitis 10.5
48 sudden sensorineural hearing loss 10.5 APOH IL6
49 recurrent corneal erosion 10.4 CXCL8 IL6
50 denture stomatitis 10.4 CXCL8 IL6

Graphical network of the top 20 diseases related to Transverse Myelitis:



Diseases related to Transverse Myelitis

Symptoms & Phenotypes for Transverse Myelitis

GenomeRNAi Phenotypes related to Transverse Myelitis according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 APOH CXCL8 IL10 IL17A TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 APOH CD27 CXCL8 IL10 IL17A TNF

MGI Mouse Phenotypes related to Transverse Myelitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.02 AQP4 CD27 IL10 IL17A IL6 MBP
2 homeostasis/metabolism MP:0005376 10.02 APOA1 APOH AQP4 IL10 IL17A IL6
3 immune system MP:0005387 9.91 AQP4 CD27 IL10 IL17A IL6 MBP
4 digestive/alimentary MP:0005381 9.88 AQP4 IL10 IL17A IL6 MMP9 TNF
5 mortality/aging MP:0010768 9.85 AMPH APOH AQP4 IL10 IL17A IL6
6 respiratory system MP:0005388 9.5 AQP4 IL10 IL17A IL6 MMP2 MMP9
7 vision/eye MP:0005391 9.17 AQP4 IL10 IL6 MBP MMP2 MMP9

Drugs & Therapeutics for Transverse Myelitis

Drugs for Transverse Myelitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4 24280-93-1 446541
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
4
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
5 Anti-Bacterial Agents Phase 4
6 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Hormones Phase 4,Phase 3,Phase 2,Phase 1
8 Anti-Infective Agents Phase 4
9 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
10 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
11 Antibiotics, Antitubercular Phase 4
12 Antitubercular Agents Phase 4
13 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
15 Analgesics Phase 4
16 Topoisomerase Inhibitors Phase 4
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Antiviral Agents Phase 4
19 Interferon-beta Phase 4
20 interferons Phase 4
21 Adjuvants, Immunologic Phase 4
22 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1
23
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-24-8 5755
24
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Phase 1 302-25-0
25
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Phase 1 2921-57-5
26
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 83-43-2 6741
27
rituximab Approved Phase 2, Phase 3,Phase 3,Phase 1 174722-31-7 10201696
28
Azathioprine Approved Phase 2, Phase 3,Phase 3 446-86-6 2265
29
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 6055-19-2, 50-18-0 2907
30
Lenograstim Approved, Investigational Phase 2, Phase 3,Phase 1 135968-09-1
31
Mesna Approved, Investigational Phase 2, Phase 3,Phase 1 3375-50-6 598
32
Ifosfamide Approved Phase 2, Phase 3,Phase 1 3778-73-2 3690
33
Sargramostim Approved, Investigational Phase 2, Phase 3 123774-72-1, 83869-56-1
34
Prednisolone hemisuccinate Experimental Phase 3,Phase 2,Phase 1 2920-86-7
35 Prednisolone acetate Phase 3,Phase 2,Phase 1
36 Autonomic Agents Phase 3,Phase 2,Phase 1
37 Neuroprotective Agents Phase 3,Phase 2,Phase 1
38 Protective Agents Phase 3,Phase 2,Phase 1
39 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
40 Antiemetics Phase 3,Phase 2,Phase 1
41 Methylprednisolone Acetate Phase 3,Phase 2,Phase 1
42 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 3
43 Antirheumatic Agents Phase 2, Phase 3,Phase 3,Phase 1
44 Antimetabolites Phase 2, Phase 3,Phase 3
45 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 3,Phase 1
46 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1
47 Immunoglobulins, Intravenous Phase 2, Phase 3,Phase 3
48 gamma-Globulins Phase 2, Phase 3,Phase 3
49 Immunoglobulins Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
50 Rho(D) Immune Globulin Phase 2, Phase 3,Phase 3

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Unknown status NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
2 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
3 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
4 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
5 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
6 A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) Completed NCT01892345 Phase 3 Eculizumab
7 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
8 Autologous Transplant To End NMO Spectrum Disorder Recruiting NCT03829566 Phase 2, Phase 3 Rituximab;Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF
9 A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders Recruiting NCT03330418 Phase 3
10 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Active, not recruiting NCT02003144 Phase 3
11 Efficacy and Safety Study as Monotherapy of Satralizumab (SA237) to Treat NMO and NMOSD Active, not recruiting NCT02073279 Phase 3 satralizumab (SA237);Placebo
12 Efficacy and Safety Study as Add-on Therapy of Satralizumab (SA237) to Treat NMO and NMOSD Active, not recruiting NCT02028884 Phase 3 satralizumab (SA237);Placebo
13 Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Active, not recruiting NCT03350633 Phase 2, Phase 3 Tocilizumab Injection;Azathioprine
14 A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Active, not recruiting NCT02200770 Phase 2, Phase 3
15 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
16 Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods) Unknown status NCT02591901 Phase 2 Uro vaxom
17 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
18 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Completed NCT02166346 Phase 2 Dalfampridine;Placebo
19 A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Completed NCT03062579 Phase 1, Phase 2 Tocilizumab
20 Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children Completed NCT00502593 Phase 2
21 Neuromyelitis Optica (NMO) & Cetirizine Completed NCT02865018 Phase 1, Phase 2 cetirizine
22 Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder Completed NCT02893111 Phase 2 Bortezomib
23 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed NCT00904826 Phase 1, Phase 2 Eculizumab
24 Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. Completed NCT01845584 Phase 2 NPB-01
25 Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Completed NCT02249676 Phase 2
26 Hematopoietic Stem Cell Transplant in Devic's Disease Active, not recruiting NCT00787722 Phase 1, Phase 2 Cyclophosphamide;G-CSF;rATG;Mesna;Rituximab;Methylprednisolone
27 Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis Not yet recruiting NCT03887273 Phase 1, Phase 2
28 Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica Terminated NCT01339455 Phase 1, Phase 2
29 Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses Unknown status NCT02087813 Phase 1 Alpha1-antitrypsin;methylprednisolone
30 Safety and Tolerability of Rituximab in Neuromyelitis Optica Completed NCT00501748 Phase 1 Rituximab
31 Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Completed NCT01777412 Phase 1 Bevacizumab
32 Central Pain Study for ABX-1431 Completed NCT03138421 Phase 1 ABX-1431 HCl;Placebo
33 C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation Completed NCT01759602 Phase 1 C1-esterase inhibitor (Cinryze)
34 Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Recruiting NCT02283671 Phase 1
35 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Active, not recruiting NCT02276963 Phase 1 Ublituximab
36 Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20 Not yet recruiting NCT03605238 Phase 1
37 Maintenance Plasma Exchange for Neuromyelitis Optica Unknown status NCT01500681
38 Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct Unknown status NCT01024985
39 Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom Completed NCT01953822
40 Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis Completed NCT03122873
41 Clinical Trial of a Serious Game for Individuals With SCI/D Completed NCT02341950 Not Applicable
42 Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine Completed NCT00258882
43 Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) Completed NCT00705614
44 Injured Spinal Cord Pressure Evaluation Study - Transverse Myelitis Recruiting NCT03336762
45 Collaborative Assessment of Pediatric Transverse Myelitis: Understand, Reveal, Educate or CAPTURE Study Recruiting NCT02144935
46 The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders Recruiting NCT01623076
47 The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS) Recruiting NCT02850705
48 Pediatric NMOSD Observational Study Recruiting NCT03766347
49 The French Multiple Sclerosis Registry Recruiting NCT02889965
50 Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02836327

Search NIH Clinical Center for Transverse Myelitis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Transverse Myelitis

Anatomical Context for Transverse Myelitis

MalaCards organs/tissues related to Transverse Myelitis:

42
Spinal Cord, Brain, Testes, T Cells, B Cells, Bone, Bone Marrow

Publications for Transverse Myelitis

Articles related to Transverse Myelitis:

(show top 50) (show all 775)
# Title Authors Year
1
Acute transverse myelitis - A rare clinical manifestation of Lyme neuroborreliosis. ( 30622896 )
2019
2
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study. ( 30903415 )
2019
3
Iatrogenic transverse myelitis in a patient with rheumatoid arthritis. ( 30898959 )
2019
4
Aquaporin-4 antibody positive short transverse myelitis associated with breast cancer. ( 30771577 )
2019
5
Concurrent Guillain-Barré syndrome, transverse myelitis and encephalitis post-Zika and multiple arboviral immunity. ( 30401491 )
2019
6
Longitudinally Extensive Transverse Myelitis (LETM) Following Varicella Infection in a 13-Year Immunocompetent Child. ( 30598680 )
2019
7
High-dose corticosteroids for acute cytomegalovirus-associated transverse myelitis in the immunocompetent patient: a case report and systematic review. ( 30610740 )
2019
8
The use of magnetic resonance imaging in the diagnosis of paediatric transverse myelitis. ( 30720201 )
2019
9
New onset transverse myelitis diagnostic accuracy and patient experiences. ( 30738277 )
2019
10
Early radiological features of severe longitudinally extensive transverse myelitis over time. ( 30878638 )
2019
11
Acute Transverse Myelitis in Children, Literature Review. ( 29696041 )
2018
12
Acute transverse myelitis following an opsoclonus-myoclonus syndrome: An unusual presentation. ( 29773357 )
2018
13
Encephalitis and transverse myelitis in dengue and chikungunya coinfection. ( 29972580 )
2018
14
Short-segment transverse myelitis lesions in a cohort of Latin American patients with neuromyelitis optica spectrum disorders. ( 29789706 )
2018
15
Systemic Lupus Erythematosus Presenting as Longitudinally Extensive Transverse Myelitis and Nephritis: A Case Report. ( 29872583 )
2018
16
Acute Transverse Myelitis Caused by Echovirus 11 in a Pediatric Patient: Case Report and Review of the Current Literature. ( 29372173 )
2018
17
Trident sign trumps Aquaporin-4-IgG ELISA in diagnostic value in a case of longitudinally extensive transverse myelitis. ( 29709797 )
2018
18
Two cases of sarcoidosis presenting as longitudinally extensive transverse myelitis. ( 29770929 )
2018
19
Neurosyphilis as a Cause of Transverse Myelitis in a Teenage Girl. ( 29602529 )
2018
20
Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses. ( 29247071 )
2018
21
Frequency of Aquaporin-4 Immunoglobulin G in Longitudinally Extensive Transverse Myelitis With Antiphospholipid Antibodies. ( 29655487 )
2018
22
Clinical features and prognoses of acute transverse myelitis in patients with systemic lupus erythematosus. ( 29294596 )
2018
23
To start immune therapy or not? An unusual presentation of longitudinally extensive transverse myelitis with pyrexia. ( 29725838 )
2018
24
MOG-antibody demyelinating diseases: a case of post-partum severe rhombencephalitis and transverse myelitis. ( 29438836 )
2018
25
Guillain-BarrAc syndrome, transverse myelitis and infectious diseases. ( 29375121 )
2018
26
Short transverse myelitis in Chinese patients with neuromyelitis optica spectrum disorders. ( 29499441 )
2018
27
Hypereosinophilic atopic transverse myelitis. ( 29888734 )
2018
28
Familial monophasic acute transverse myelitis due to the pathogenic variant in <i>VPS37A</i>. ( 29473047 )
2018
29
Natural history of longitudinally extensive transverse myelitis in 35 Hispanic patients with systemic lupus erythematosus: good short-term functional outcome and paradoxical increase in long-term mortality. ( 29635997 )
2018
30
Longitudinally extensive transverse myelitis following dengue virus infection: A rare entity. ( 29536963 )
2018
31
CLIPPERS with longitudinally extensive transverse myelitis: Role of T versus B cells. ( 29406923 )
2018
32
Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis. ( 29710213 )
2018
33
Cytomegalovirus associated longitudinally extensive transverse myelitis and acute hepatitis in an immunocompetent adult. ( 29396069 )
2018
34
MRI Features of Aquaporin-4 Antibody-Positive Longitudinally Extensive Transverse Myelitis: Insights into the Diagnosis of Neuromyelitis Optica Spectrum Disorders. ( 29449281 )
2018
35
Reversible paraspinal muscle hyperintensity in anti-MOG antibody-associated transverse myelitis. ( 29114566 )
2018
36
Effects of electroacupuncture on bladder and bowel function in patients with transverse myelitis: a prospective observational study. ( 29909400 )
2018
37
Longitudinally Extensive Transverse Myelitis. ( 29862450 )
2018
38
Longitudinally extensive transverse myelitis with pulmonary tuberculosis: Two case reports. ( 29505015 )
2018
39
Acute transverse myelitis following scrub typhus: A case report and review of the literature. ( 29350608 )
2018
40
Anti-Myelin Oligodendrocyte Glycoprotein Antibody Associated With Gray Matter Predominant Transverse Myelitis Mimicking Acute Flaccid Myelitis: A Presentation of Two Cases. ( 30077551 )
2018
41
Case Report: Acute Transverse Myelitis after Zika Virus Infection. ( 30277201 )
2018
42
Retained Glass Fragment in the Cervical Spinal Canal in a Patient with Acute Transverse Myelitis: A Case Report and Literature Review. ( 30009065 )
2018
43
Primary Epstein-Barr virus infection in immunocompetent patients with acute transverse myelitis and a combination of polyradiculitis and anterior horn syndrome as neurological manifestations. ( 30158264 )
2018
44
Intracranial dural arteriovenous fistula mistaken as cervical transverse myelitis. ( 30518532 )
2018
45
Transverse Myelitis and Guillain-Barré Syndrome Associated with Cat-Scratch Disease, Texas, USA, 2011. ( 30124417 )
2018
46
Primary Bone Marrow Diffuse Large B-cell Lymphoma Presenting as Transverse Myelitis. ( 30447708 )
2018
47
Concurrent Guillain-Barré syndrome, transverse myelitis and encephalitis post-Zika: A case report and review of the pathogenic role of multiple arboviral immunity. ( 30423542 )
2018
48
Concurrent Guillain-Barré syndrome, transverse myelitis and encephalitis post-Zika: A case report and review of the pathogenic role of multiple arboviral immunity. ( 30292020 )
2018
49
Erratum to 'Concurrent Guillain-Barré syndrome, transverse myelitis and encephalitis post-Zika: A case report and review of the pathogenic role of multiple arboviral immunity', Journal of the Neurological Sciences, Volume 395, 15 December 2018, Pages 47-53. ( 30401470 )
2018
50
A case of anti-MOG antibody-positive unilaterally dominant meningoencephalitis followed by longitudinally extensive transverse myelitis. ( 30071506 )
2018

Variations for Transverse Myelitis

Expression for Transverse Myelitis

Search GEO for disease gene expression data for Transverse Myelitis.

Pathways for Transverse Myelitis

Pathways related to Transverse Myelitis according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.32 CD27 CXCL8 IL10 IL17A IL6 TNF
2
Show member pathways
13.27 CD27 CXCL8 IL10 IL17A IL6 MMP2
3
Show member pathways
13.23 CD27 CXCL8 IL10 IL17A IL6 TNF
4
Show member pathways
12.82 CXCL8 IL10 IL17A IL6 TNF
5
Show member pathways
12.55 IL10 IL17A IL6 MMP2 TNF
6
Show member pathways
12.53 IL10 IL17A IL6 TNF
7
Show member pathways
12.38 IL10 IL17A IL6 TNF
8
Show member pathways
12.28 CXCL8 IL17A IL6 MMP9 TNF
9
Show member pathways
12.24 CXCL8 IL10 IL17A IL6 TNF
10 12.16 IL6 MMP2 MMP9 TNF
11 12.1 AQP4 CXCL8 IL10 IL6 TNF
12
Show member pathways
12.03 IL10 IL17A IL6 TNF
13 12.02 MMP2 MMP9 TNF
14
Show member pathways
12.01 CXCL8 IL10 IL17A IL6
15
Show member pathways
12.01 IL6 MMP2 MMP9 TNF
16 11.94 IL10 IL6 TNF
17 11.91 IL6 MMP9 TNF
18 11.89 CXCL8 IL6 MMP2 TNF
19 11.87 CXCL8 IL10 IL6 TNF
20
Show member pathways
11.86 MMP2 MMP9 TNF
21
Show member pathways
11.83 CXCL8 IL17A IL6
22 11.83 CXCL8 IL17A IL6 TNF
23 11.75 IL10 IL17A TNF
24 11.75 CXCL8 MMP2 MMP9
25 11.72 CXCL8 IL10 IL6 TNF
26 11.71 IL10 IL6 TNF
27 11.7 CXCL8 MMP2 MMP9
28 11.64 CXCL8 IL6 MMP2 MMP9
29 11.62 CXCL8 MMP2 MMP9
30 11.57 CXCL8 IL6 MMP2
31 11.57 IL10 IL17A IL6 MMP9 TNF
32 11.56 CXCL8 IL6 TNF
33 11.53 IL6 MMP2 TNF
34 11.51 AQP4 CXCL8 IL6 MBP MMP9 TNF
35 11.47 CXCL8 IL10 IL6 TNF
36 11.45 CXCL8 IL10 IL6 TNF
37 11.45 CXCL8 IL6 MMP2 MMP9 TNF
38 11.42 IL6 MMP2 MMP9 TNF
39 11.35 IL10 IL6 TNF
40
Show member pathways
11.35 CXCL8 IL6 MMP2 MMP9 TNF
41 11.3 IL17A IL6 TNF
42 11.27 APOA1 IL10 IL6 TNF
43 11.24 IL10 IL6 TNF
44 11.22 CXCL8 IL10 IL17A IL6 MMP2 MMP9
45 11.2 CXCL8 IL6 MMP2 MMP9
46 11.14 CXCL8 IL10 IL17A IL6 TNF
47 11.03 CXCL8 IL6 TNF
48 10.96 CXCL8 IL10 IL17A IL6 TNF

GO Terms for Transverse Myelitis

Cellular components related to Transverse Myelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.67 AQP4 CD27 IL17A TNF
2 cell surface GO:0009986 9.65 APOA1 APOH CD27 MBP TNF
3 extracellular space GO:0005615 9.61 APOA1 APOH CXCL8 IL10 IL17A IL6
4 collagen-containing extracellular matrix GO:0062023 9.46 APOA1 APOH MMP2 MMP9
5 very-low-density lipoprotein particle GO:0034361 9.4 APOA1 APOH
6 chylomicron GO:0042627 9.32 APOA1 APOH
7 extracellular region GO:0005576 9.32 APOA1 APOH CD27 CXCL8 IL10 IL17A

Biological processes related to Transverse Myelitis according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.85 CXCL8 IL10 IL17A IL6 TNF
2 inflammatory response GO:0006954 9.8 CXCL8 IL10 IL17A IL6 TNF
3 immune response GO:0006955 9.8 CXCL8 IL10 IL17A IL6 MBP TNF
4 cellular response to lipopolysaccharide GO:0071222 9.73 CXCL8 IL10 IL6 TNF
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.72 IL10 IL6 TNF
6 response to glucocorticoid GO:0051384 9.67 IL10 IL6 TNF
7 positive regulation of osteoclast differentiation GO:0045672 9.6 IL17A TNF
8 positive regulation of chemokine production GO:0032722 9.59 IL6 TNF
9 embryonic digestive tract development GO:0048566 9.58 CXCL8 TNF
10 positive regulation of glial cell proliferation GO:0060252 9.58 IL6 TNF
11 negative regulation of growth of symbiont in host GO:0044130 9.57 IL10 TNF
12 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.56 IL10 TNF
13 response to molecule of bacterial origin GO:0002237 9.54 CXCL8 IL10
14 negative regulation of lipid storage GO:0010888 9.52 IL6 TNF
15 endothelial cell apoptotic process GO:0072577 9.51 IL10 TNF
16 positive regulation of neuroinflammatory response GO:0150078 9.48 IL6 TNF
17 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.46 IL10 MMP2 MMP9 TNF
18 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.43 APOA1 IL10 MBP
19 receptor biosynthetic process GO:0032800 9.37 IL10 TNF
20 cytokine-mediated signaling pathway GO:0019221 9.17 CXCL8 IL10 IL17A IL6 MMP2 MMP9
21 negative regulation of cytokine secretion involved in immune response GO:0002740 9.13 APOA1 IL10 TNF

Molecular functions related to Transverse Myelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.8 AMPH APOA1 APOH AQP4 CD27 CXCL8
2 phospholipid binding GO:0005543 9.33 AMPH APOA1 APOH
3 cytokine activity GO:0005125 9.02 CXCL8 IL10 IL17A IL6 TNF

Sources for Transverse Myelitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....